Cite
HARVARD Citation
Foley, J. et al. (2022). Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet neurology. 21 (7), pp. 608-619. [Online].